The U.S. Food and Drug Administration has cleared the iCam non-mydriatic compact fundus camera from Optovue, according to a company news release.The device, which offers joystick control, image review and electronic medical record communications, can produce 45° color fundus images of the eye and external structures.
Month: February 2013
AAO: Study backs recommendation against routine genetic testing for AMD
Certain gene variants may predict whether a person will develop age-related macular degeneration, but they do not predict how that person would respond to anti-VEGF therapy, a study found. The American Academy of Ophthalmology said this reinforces its recommendation against routine genetic testing for AMD. “The Academy advises against routine genetic testing for AMD and other complex eye disorders until specific treatment or monitoring strategies have been shown in clinical trials to be of benefit to people with specific, risk-linked genotypes,” the AAO said in a press release.
Allergan launches preservative-free lubricant eye drops for dry eye
Allergan is expanding its dry eye treatment line with a preservative-free lubricant formulation of the Refresh Optive Advanced brand, according to a company news release.
Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis
The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to sever…
No Link Found Between Genetic Risk Factors And 2 Top Wet AMD Treatments
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis™ and Avastin™, the two medications most widel…
Castle Biosciences launches MyUvealMelanoma website
Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common f…
Adalimumab for the Treatment of Non-infectious Uveitis
Is adalimumab an effective and safe therapeutic option in the treatment of uveitis, even if patients were non-responsive to previous other anti-TNF therapy? The British Journal of Ophthalmology
Evaluation of Moxifloxacin 0.5% in Treatment of Nonperforated Bacterial Corneal Ulcers: A Randomized Controlled Trial – Corrected Proof
Purpose:
To compare the equivalence of moxifloxacin 0.5% with a combination of fortified cefazolin sodium 5% and tobramycin sulfate 1.3% eye drops in the treatment of moderate bacterial corneal ulcers.
Design:
Randomized, controlled, equivalence cl…
Predictive Value in Retinal Vein Occlusions of Early Versus Late or Incomplete Ranibizumab Response Defined by Optical Coherence Tomography – Corrected Proof
Purpose:
To determine if optical coherence tomography (OCT) at baseline or month 3 in the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efficacy and Safety (BRAVO) and Treatment of Macular Edema following Central Retinal Vein Occlusion: Evaluation of Efficacy and Safety (CRUISE) studies provides information that predicts visual outcome.
Design:
Post hoc analysis from 2 prospective, randomized, controlled clinical trials.
Participants:
Three hundred ninety-seven patients from the BRAVO study and 392 patients from the CRUISE study.
Methods:
Time-domain OCT imaging data were analyzed.
Main Outcome Measures:
Mean change from baseline best-corrected visual acuity (BCVA) letter score (Read more...)
Body Stature Growth Trajectories during Childhood and the Development of Myopia – Corrected Proof
Purpose:
Stature at a particular age can be considered the cumulative result of growth during a number of preceding growth trajectory periods. We investigated whether height and weight growth trajectories from birth to age 10 years were related to refractive error at ages 11 and 15 years, and eye size at age 15 years.
Design:
Prospective analysis in a birth cohort.
Participants:
Children participating in the Avon Longitudinal Study of Parents and Children (ALSPAC) U.K. birth cohort (minimum N = 2676).
Methods:
Growth trajectories between birth and 10 years were modeled from a series of height and weight measurements (N (Read more...)
Limited Sight Restored by Retinal Implant
(MedPage Today) — The FDA has approved the first implantable device to treat advanced retinitis pigmentosa, the agency announced.
FDA Approves Retinal Prosthesis, a ‘Bionic Eye’
The FDA has approved the Argus II Retinal Prosthesis System, the first ‘bionic eye,’ allowing US implants to begin in people blinded by retinitis pigmentosa. FDA Approvals
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein
Source: Cochrane
Area: Evidence > Drug Class Focused Reviews
Background
Branch retinal vein occlusion (BRVO) is one of the most common occurring retinal vascular abnormalities. The pathogenesis of BRVO is thought to involve both retinal vein compression and damage to the vessel wall, possibly leading to thrombus formation at sites where retinal arterioles cross retinal veins. The most common cause of visual loss in patients with BRVO is macular oedema (MO). Grid or focal laser photocoagulation has been shown to reduce the risk of visual loss and improve visual acuity (Read more...)
Does Aspirin Cause Macular Degeneration?
Australian researchers claim aspirin use may cause macular degeneration. Many take aspirin to prevent heart attacks. What can you do?
FDA approves Argus II Retinal Prosthesis System
The Argus II Retinal Prosthesis System from Second Sight Medical Products has been approved by the U.S. Food and Drug Administration.The system, designed to treat adults with advanced retinitis pigmentosa, includes an external small video camera, video processing unit and transmitter fixed to eyeglasses, along with electrodes implanted internally onto the patient’s retina, according to an FDA press release.
Amblyopia screening guidelines updated
The American Association for Pediatric Ophthalmology and Strabismus, the professional body for pediatric eye care, has issued revised guidelines for preschool vision screening based on new evidence.
Quarterly revenue increases for Carl Zeiss Meditec
Carl Zeiss Meditec reported €219 million in revenue for the first quarter of the financial year, up 4% from €210.3 million in the same quarter of the previous year, according to a company news release.Earnings before interest and taxes increased 10.2% to €31.2 million from €28.3 million.
Durability of anti-VEGF regimen may increase with low-voltage X-ray irradiation
MIAMI — In previously treated wet age-related macular degeneration, low-voltage X-ray irradiation may increase the durability of a ranibizumab treatment regimen, a speaker said here.In a study led by Darius M. Moshfeghi, MD, 19 patients were given a single treatment of noninvasive, externally delivered low-voltage X-ray irradiation. The 24-Gy dose was administered to patients with neovascular AMD who had been previously treated with intravitreal Lucentis (ranibizumab, Genentech).
New anti-VEGF may improve vision in some patients initially treated with other agents
MIAMI — Some patients currently being treated with bevacizumab or ranibizumab may experience an improvement in visual acuity if their treatment regimen is switched to aflibercept, a speaker said here. Presenting four patient cases, Jason S. Slakter, MD, said Eylea (aflibercept, Regeneron) may create a “marked improvement” in the eye’s anatomy.
Queen’s Study Aims To Use Stem Cells To Help Save Sight Of Diabetes Sufferers
Scientists at Queen’s University Belfast are hoping to develop a novel approach that could save the sight of millions of diabetes sufferers using adult stem cells. Currently millions of diabetics worldwide are at risk of sight loss due to a condition …